Neurizon Therapeutics Limited
0.08
AUD
+0.00
(+2.60%)
ISIN
AU0000357261
Return %
Stock
S&P 500
1Y
-38.19
14.20
3Y
7.13
81.12
5Y
-16.30
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Chris Bremer
- Full Time Employees
- 36
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 385 Bourke Street Melbourne VIC Australia 3000
- IPO Date
- Oct 5, 2001
- Website
- pharmaust.com
- Similar Companies
- Business
- Neurizon Therapeutics Limited is a biotechnology company focused on the discovery and development of therapeutics for neurodegenerative diseases, with a primary emphasis on NUZ-001 (S-Monepantel) and related pipelines aimed at conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. The company advances drug discovery IP, translational research, and clinical development programs, leveraging a platform that supports preclinical and clinical-stage assets as well as related contract research capabilities. Main Products and Services: NUZ-001 (S-Monepantel) developmental program targeting ALS and other neurodegenerative diseases; drug discovery intellectual property and platform technologies for neurodegenerative disease therapeutics; preclinical pharmacology and toxicology studies; clinical trial coordination and regulatory support across Phase I/II activities; manufacturing scale-up and process development for GMP-ready materials; collaboration and licensing arrangements for translational research data and asset sharing; contract medicinal chemistry and related R&D services for pharmaceutical clients; strategic partnerships and joint development arrangements for neurodegenerative programs; licensing, co-development, and commercialization agreements related to NUZ-001 and other discovery programs. Latest Major Company Changes: Strategic licensing agreements and collaborations, including a worldwide exclusive licensing deal with a major animal health company to support expanded development and potential cross-species applications; progress in regulatory milestones such as FDA interactions leading to provisionally cleared or lifted clinical holds enabling entry into platform trials; securing non-dilutive and other funding arrangements to support GMP manufacturing, late-stage development readiness, and capital runway; ongoing corporate rebranding and corporate structure evolution following a name change to reflect a renewed focus on neurodegenerative disease therapeutics; expansion of manufacturing and quality systems to support scalable production of NUZ-001; advancements in clinical trial readiness, including initiation of GMP manufacturing activities and preparation for platform trial participation. Additional Context: Industry and business segments: biotechnology, pharmaceutical research and development; neurodegenerative disease therapeutics; contract research and chemistry services. Target markets and customer types include pharmaceutical and biotechnology companies seeking novel neurodegenerative disease treatments, academic partnerships, and translational research collaborations. Geographic operations span Australia, Europe, the United States, and international collaborators, with headquarters in Melbourne, Australia, and a research-focused footprint across multiple regions. Subsidiaries and parent relationships reflect a corporate structure aligned with the pharmaceutical and biotech sectors, including licensing and collaboration entities designed to advance NUZ-001 and related programs. The company emphasizes clinical-stage development, translational science, and strategic partnerships as core drivers of growth.
Company News
Adobe trades revenue for reach as AI monetization stays elusive
Neurizon passes halfway mark in HEALEY ALS trial as NUZ-001 dosing accelerates
Flutter to quit LSE and trade solely in New York
HEALEY ALS Platform Trial Regimen I expands to 240 participants